Targeted clinical studies are critically required to assess the effectiveness and safety of pharmacological interventions, notably GLP-1 receptor agonists and SGLT2 inhibitors, primarily in lean NAFLD/NASH populations. Here, GLP1R is linked to metabolic dysfunction-associated steatotic liver disease.